According to the company, the approval will expand the use of Skyrizi to patients with psoriatic arthritis who are living with the debilitating combination of skin and joint symptoms
Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading the development and commercialization of Skyrizi globally.
Shares were flat in the after-hours session.
Price: 132, Change: +0.02, Percent Change: +0.02
|Street Color: Global Calendar For Week Ending May 20|
|Ryder System Receives $4.4 Billion Cash Buyout Propo...|
|Payoneer Shares Rally After Q1 Beats Expectations, 2...|
|Market Chatter: Alibaba Group's Venture in Russia Re...|
|Research Alert: CFRA Raises View On Paycom Software ...|